Collaborations and Other Arrangements (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	$ 6,488.0	$ 6,740.1	$ 14,298.0	$ 13,545.7
China
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	352.1	522.5	758.5	884.7
Jardiance
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	461.0	356.5	880.4	668.5
Basaglar
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	174.2	210.7	365.7	457.3
Trajenta
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	97.1	89.2	189.2	183.8
Olumiant®
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	186.2	208.4	441.8	402.2
COVID-19 Antibodies
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	129.1	148.9	1,598.9	959.1
Tyvyt®
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	73.6	$ 105.0	159.0	$ 214.6
Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative | Jardiance
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential achievements	126.1		126.1		$ 136.1
Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative | Basaglar
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential achievements	(140.0)		(140.0)		(149.3)
Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative | Trajenta
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential achievements	75.8		$ 75.8		88.5
Royalty Agreement Terms | Olumiant®
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, rights and obligations, percentage (up to)			20.00%
Milestone Payments, Capitalized as Intangible Assets | Olumiant®
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential achievements	330.0		$ 330.0		260.0
Milestone Payments, Capitalized as Intangible Assets | Tyvyt®
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential achievements	120.0		120.0		$ 40.0
Milestone Payments, Development and Regulatory | Lebrikizumab
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential achievements	85.0		85.0
Milestone Payments, Sales-based | Olumiant®
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential achievements	100.0		100.0
Milestone Payments, Sales-based | Lebrikizumab
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential achievements	1,250.0		1,250.0
Innovent Biologics, Inc. | Milestone Payments, Success-based Regulatory and Sales-based | Tyvyt® | Non-CHINA
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential achievements	825.0		825.0
Innovent Biologics, Inc. | Milestone Payments, Success-based Regulatory and Sales-based | Tyvyt® | China
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential achievements	115.0		115.0
Roche | Milestone Payments, Development and Regulatory | Lebrikizumab
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential achievements	180.0		180.0
Roche | Milestone Payments, Sales-based | Lebrikizumab
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential achievements	$ 1,030.0		$ 1,030.0